logo-loader
ContraVir Pharmaceuticals

ContraVir Pharmaceuticals stock soars after its Hepatitis B drug appears in medical journal article

The article discusses the discovery that its drug CRV431 reduced the amount of Hepatitis B DNA in mice

Person holding a liver
The article is entitled, “The Cyclophilin Inhibitor CRV431 Inhibits Liver HBV DNA and HBsAg in Transgenic Mice”

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) shares popped after an article highlighting the success of its Hepatitis B treatment was published in a medical journal.

The article, written by the company and published in the journal PLOS ONE, discusses the discovery that its drug CRV431 reduced the amount of Hepatitis B DNA in mice.

The New Jersey-based company's stock jumped nearly 34% to $9.38.

In the study, transgenic mice were treated with CRV431, an inhibitor of the cyclophilin family of proteins. Transgenic mice have been genetically modified with certain human genes.

READ: Traders cash in on NoveBay Pharmaceuticals a day after the stock exploded tenfold

Mice treated with CRV431 saw a reduction in HBV DNA between 13% and 91%, depending on the dose level, compared to the control group.

“CRV431 interferes with the way that HBV hijacks our body’s molecules to amplify virus replication, which is distinct from traditional antiviral drugs such as tenofovir that bind only to HBV proteins,” CEO Robert Foster said. “Additionally, CRV431 reduced serum levels of HBsAg, an important prognostic indicator, which is typically not decreased by nucleotide drugs.”

Tenofovir is another ContraVir drug that was tested in the study, used separately and with CRV431. Mice treated with the lowest doses of both drugs saw an 80% reduction in HBV DNA levels compared to the control group.

The article is entitled, “The Cyclophilin Inhibitor CRV431 Inhibits Liver HBV DNA and HBsAg in Transgenic Mice.”

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: ContraVir Pharmaceuticals

Price: £0.00

Market: NASDAQ
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

2 days, 8 hours ago

2 min read